VC: Genizon rounds up $31M



Genizon rounds up $31M

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Genizon BioSciences
Canada

$31M
Fifth

BTF

Genizon's has DNA resources and a platform that is applicable to many stages of drug development.

Corthera
San Mateo, CA

$23M
Third

Caxton Advantage Life Sciences Fund

Corthera lead therapy is Relaxin, which is being developed to treat heart failure.

Primera Biosystems
Providence, RI

$21M
Second

Abingworth

Primera has been developing new technology related to gene expression, DNA/RNA analysis, micro RNA analysis, mutation analysis and methylated DNA analysis.

Arcion Therapeutics
Baltimore

$8.8M
First

CMEA Ventures and InterWest Partners

Arcion has been developing ARC-4558, a topical gel to treat moderate and severe pain caused by diabetic neuropathy.

Follica
Boston

$5.5M
First

Interwest Partners

Follica is developing a therapy for androgenetic alopecia and other hair follicle disorders.

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."